Published in Telemedicine Week, May 8th, 2007
Study 1: Research findings, "Synthesis and biological evaluation of [18F]bicalutamide, 4-[76Br]bromobicalutamide, and 4-[76Br]bromo-thiobicalutamide as non-steroidal androgens for prostate cancer imaging," are discussed in a new report. "Androgen receptors (AR) are overexpressed in most primary and metastatic prostate cancers. To develop a nonsteroidal AR-mediated imaging agent, we synthesized and radiolabeled several analogs of the potent antiandrogen bicalutamide: [18F]bicalutamide, 4-[76Br]bromobicalutamide, and [76Br]bromo-thiobicalutamide," scientists in the United States report.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Telemedicine Week